Literature DB >> 30281991

Cabozantinib in Hepatocellular Carcinoma.

Ghassan K Abou-Alfa1, Anne E Borgman-Hagey2, Robin K Kelley3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30281991     DOI： 10.1056/NEJMc1810178

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  3 in total

Review 1.  Implications of Immunotherapy in Hepatobiliary Tumors.

Authors:  Aline Gottlieb; Jan Best; Ali Canbay
Journal:  Visc Med       Date:  2019-02-08

2.  Editorial comment on: "Systemic treatment of hepatocellular carcinoma: an EASL position paper".

Authors:  Daniel H Ahn; Tanios Bekaii-Saab
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 7.293

Review 3.  Immunmodulatory Treatment Strategies of Hepatocellular Carcinoma: From Checkpoint Inhibitors Now to an Integrated Approach in the Future.

Authors:  Matthias Ocker; Christian Mayr; Tobias Kiesslich; Sebastian Stintzing; Daniel Neureiter
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.